Broome CM et al. Efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia: Results of a phase 3, multicenter, double-blinded, placebo-controlled, randomized clinical trial (ADVANCE IV). Blood 2022;140(supp 1):6-8. Abstract

Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 2021;10:313-21. Abstract

Cooper N et al. VAYHIT1: A multicenter, randomized, double-blind, phase III trial of ianalumab versus placebo in addition to first-line corticosteroids in patients with primary immune thrombocytopenia (ITP). EHA 2023;Abstract PB2636.

Jiang D et al. Changing paradigms in ITP Management: Newer tools for an old disease. Transfus Med Rev 2022;36(4):180-94. Abstract

Kuter DJ et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. New Engl J Med 2022;386(15):1421-31. Abstract

Mageau A et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment. Am J Hematol 2021;97(10):10-17. Abstract

Zaja F et al. VAYHIT2: A randomized, double-blind, phase III trial of ianalumab vs placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line steroid treatment. EHA 2023;Abstract PB2625.